

# Human BAFF Sandwich ELISA Kit Datasheet

Please read it entirely before use

Catalogue Number: KE00215 Size: 96T Sensitivity: 0.5 pg/mL Range: 7.8-500 pg/mL Usage: For the quantitative detection of human BAFF concentrations in serum, plasma and cell culture supernatant.

This product is for research use only and not for use in human or animal therapeutic or diagnostic.




| Table of content                 | pa | ge  |
|----------------------------------|----|-----|
| 1. Background                    |    | • 3 |
| 2. Principle                     |    | • 3 |
| 3. Required Materials            |    | • 3 |
| 4. Kit Components and Storage    |    | 4   |
| 5. Safety Notes                  |    | • 4 |
| 6. Sample Collection and Storage |    | • 4 |
| 7. Regent Preparation            |    | • 5 |
| 8. Assay Procedure Summary       |    | • 6 |
| 9. Validation Data               |    | • 7 |
| 9.1 Standard curve               |    | • 7 |
| 9.2 Precision                    |    | • 7 |
| 9.3 Recovery                     |    | • 8 |
| 9.4 Sample values                |    | 8   |
| 9.5 Sensitivity                  |    | • 8 |
| 9.6 Linearity                    |    | • 9 |
| 10. References                   |    | • 9 |

ptglab.com

### 1. Background

BAFF, or B cell-activating factor, also known as B lymphocyte stimulator (BlyS; trademark of Human Genome Sciences, Rockville, MD), TALL-1, THANK, and TNFSF13B, is a member of the tumor necrosis factor (TNF) superfamily and is best known for its role in the survival and maturation of B cells. The full-length molecule of BAFF is a 285-amino acid (285 aa) peptide with 2 potential N-glycosylation sites at residues 124 and 242. Cleavage downstream from aa 124 releases a first form of nonglycosylated BAFF, and possibly a second form glycosylated at aa 242. A 152-amino acid form can also be shed from the membrane and is detectable in human serum. Studies on BAFF transgenic mice and patients with rheumatoid diseases indicate that overexpression of BAFF is linked to the development of autoimmune pathology. BAFF expression was detectable in heart, skeletal muscle, pancreas, kidney, skin with adipose tissue, and liver at similar levels as in the CNS.

#### 2. Principle



# Sandwich ELISA structure (Detection antibody labeled with biotin)

A capture antibody is pre-coated onto the bottom of wells which binds to analyte of interest. A detection antibody labeled with biotin also binds to the analyte. Streptavidin-HRP binds to the biotin. TMB acts as the HRP substrate and the solution color will change from colorless to blue. A stop solution containing sulfuric acid turns solution yellow. The color intensity is proportional to the quantity of bound protein which is measurable at 450 nm with the correction wavelength set at 630 nm.

# 3. Required Materials

3.1 A microplate reader capable of measuring absorbance at 450 nm with the correction wavelength set at 630 nm.

3.2 Calibrated, adjustable precision pipettes and disposable plastic tips. A manifold multi-channel pipette is recommended for large assays.

- 3.3 Plate washer: automated or manual.
- 3.4 Absorbent paper towels.
- 3.5 Glass or plastic tubes to prepare standard and sample dilutions.

3.6 Beakers and graduated cylinders.

3.7 Log-log or semi-log graph paper or computer and software for ELISA data analysis. A four-parameter logistic (4-PL) curve-fit is recommended.

ptglab.com

# 4. Kit Components and Storage

| Microplate - antibody coated 96 - well microplate (8 well × 12 strips) | 1 plate   | Unopened Kit:                    |
|--|-----------|----------------------------------|
| Protein standard - 500 pg/bottle; lyophilized                          | 2 bottles |                                  |
| Detection antibody, biotinylated (100×) - 120 µL/vial*                 | 1 vial    | Store at 2-8°C for 6 months or - |
| Streptavidin-horseradish peroxidase (HRP) (100×) - 120 µL/vial*        | 1 vial    | 20°C for 12 months.              |
| Sample Diluent PT 3 - 30 mL/bottle.                                    | 1 bottle  | Opened Kit:                      |
| Detection Diluent - 30 mL/bottle                                       | 1 bottle  | All reagents stored at 2-8°C for |
| Wash Buffer Concentrate (20×) - 30 mL/bottle                           | 1 bottle  | C C                              |
| Tetramethylbenzidine Substrate (TMB) - 12 mL/bottle                    | 1 bottle  | 7 days.                          |
| Stop Solution - 12 mL/bottle   | 1 bottle  | Please use a new standard        |
| Plate Cover Seals  | 4 pieces  | for each assay.                  |

\* Centrifugation immediately before use

# 5. Safety Notes

5.1 Avoid any skin and eye contact with Stop Solution and TMB. In case of contact, wash thoroughly with water.

5.2 Do not use the kit after the expiration date.

5.3 Do not mix or substitute reagents or materials from other kit lots or other sources.

5.4 Be sure to wear protective equipment such as gloves, masks and goggles during the experiment.

5.5 When using an automated plate washer, adding a 30 second soak period following the addition of Wash Buffer to improve assay precision

# 6. Sample Collection and Storage

6.1 Serum: Allow blood samples to clot for 30 minutes, followed by centrifugation for 15 minutes at 1000xg. Clear serum can be assayed immediately or aliquoted and stored at -20°C. Avoid repeated freeze-thaw cycles.

6.2 Plasma: Use EDTA, heparin, or citrate as an anticoagulant for plasma collection. Centrifuge for 15 minutes at 1000xg within 30 minutes of collection. The plasma can be assayed immediately or aliquoted and stored at -20°C. Avoid repeated freeze-thaw cycles.

6.3 Cell Culture Supernatant: Remove particulates by centrifugation for 5 minutes at 500xg and assay immediately or aliquot and store samples at  $\leq$  -20°C. Avoid repeated freeze-thaw cycles.

# 7. Regent Preparation

7.1 Wash Buffer (1X): If crystals have formed in the concentrate, warm to room temperature and mix gently until the crystals have completely dissolved. Add 30 mL of Wash Buffer Concentrate(20X) to 570 mL deionized or distilled water to prepare 1X Wash Buffer.

7.2 Detection Antibody (1X): Dilute 100X Detection Antibody 1:100 using Detection Diluent prior to assay. Suggested 1:100 dilution: 10 µL 100X Detection Antibody + 990 µL Detection Diluent (Centrifuge the 100 X Detection Antibody solution for a few seconds prior to use).


7.3 Streptavidin-HRP (1X): Dilute 100X Streptavidin-HRP 1:100 using Detection Diluent prior to assay. Suggested 1:100 dilution: 10 µL 100X Streptavidin-HRP + 990 µL Detection Diluent (Centrifuge the 100X Streptavidin-HRP solution for a few seconds prior to use).

7.4 Sample Dilution: Different samples should be diluted with corresponding Sample Diluent, samples may require further dilution if the readout values are higher than the highest standard OD reading. Variations in sample collection, processing and storage may affect the results of the measurement.

Recommended Dilution for different sample types: 1:8 or 1:16 is recommended for human serum and plasma; 1:32 or 1:64 is recommended for cell culture supernatant.

#### 7.5 Standard Serial Dilution:

Add 1 mL Sample Diluent PT 3 in protein standard.



| og/mL |
|-------|
|       |

62.5 pg/mL

| 6 | pg/mL | 7.8 | pg |
|---|-------|-----|----|

| Add # μL of Standard<br>diluted in the previous<br>step | -       | 500 μL | 500 μL | 500 μL | 500 µL | 500 µL | 500 μL |
|---|---------|--------|--------|--------|--------|--------|--------|
| # μL of Sample Diluent<br>PT 3                          | 1000 µL | 500 μL | 500 μL | 500 μL | 500 µL | 500 µL | 500 μL |
|   | "sd7"   | "sd6"  | "sd5"  | "sd4"  | "sd3"  | "sd2"  | "sd1"  |

#### 8. Assay Procedure Summary

Bring all reagents to room temperature before use (Detection antibody and Streptavidin-HRP can be used immediately). To avoid cross-contamination, change pipette tips between additions of each standard level, between sample additions, and between reagent additions. Also, use separate reservoirs for each reagent. 8.1 Take out the required number of microplate strips and return excess strips to the foil pouch containing the drying reagent pack and reseal; store at 4°C immediately. Microplate strips should be used in one week.

8.2 Preset the layout of the microplate, including control group, standard group and sample group, add 100 µL of each standard and sample to the appropriate wells. (Make sure sample addition is uninterrupted and completed within 5 to 10 minutes, It is recommended to assay all standards, controls, and samples in duplicate).

8.3 Seal plate with cover seal, pressing it firmly onto top of microwells. Incubate the plate for 2 hours at 37°C in a humid environment.

8.4 Wash

1) Gently remove the cover seal. Discard the liquid from wells by aspirating or decanting. Remove any residual solution by tapping the plate a few times on fresh paper towels.

2) Wash 4 times with 1X Wash Buffer, using at least 350-400 µL per well. Following the last wash, firmly tap plates on fresh towels 10 times to remove residual Wash Buffer. Avoid getting any towel fibers in the wells or wells drying out completely.
8.5 Add 100 µL of 1X Detection Antibody solution (refer to Reagent Preparation7.2) to each well. Seal plate with cover seal and incubate for 1 hour at 37°C in a humid environment.

8.6 Repeat wash step in 8.4.

8.7 Add 100 µL of 1X Streptavidin-HRP solution (refer to Reagent Preparation7.3) to each well. Seal plate with cover seal and incubate the plate for 40 minutes at 37°C in a humid environment.

8.8 Repeat wash step in 8.4.

8.9 Signal development: Add 100 μL of TMB substrate solution to each well, protected from light. Incubate for 15 to
20 minutes. Substrate Solution should remain colorless until added to the plate.

8.10 Quenching color development: Add 100 µL of Stop Solution to each well in the same order as addition of the TMB substrate. Mix by tapping the side of the plate gently. NB: Avoid skin and eye contact with the Stop solution.

8.11 Read results: Immediately after adding Stop solution read the absorbance on a microplate reader at a wavelength of 450 nm. If possible, perform a double wavelength readout (450 nm and 630 nm).


8.12 Data analysis: Calculate the average of the duplicate readings (OD value) for each standard and sample, and subtract the average of the zero standard absorbance. Construct a standard curve by plotting the mean absorbance for each standard on the y-axis against the concentration on the x-axis, use four-parameter logistic curve- fit (4-PL) analysis to do this. If the samples have been diluted, the OD readout from the standard curve must be multiplied by the dilution factor used.

| Step | Reagent  | Volume | Incubation | Wash        | Notes   |  |  |  |
|------|--|--------|------------|-------------|---|--|--|--|
| 1    | Standard and Samples   | 100 µL | 120 min    | 4 times     | Cover Wells incubate at 37°C in a humid environment |  |  |  |
| 2    | Diluent Antibody Solution  | 100 µL | 60 min     | 4 times     | Cover Wells incubate at 37°C in a humid environment |  |  |  |
| 3    | Diluent HRP Solution   | 100 µL | 40 min     | 4 times     | Cover Wells incubate at 37°C in a humid environment |  |  |  |
| 4    | TMB Substrate  | 100 µL | 15-20 min  | Do not wash | Incubate in the dark at 37°C                        |  |  |  |
| 5    | Stop Solution  | 100 µL | 0 min      | Do not wash | -   |  |  |  |
| 6    | 6 Read plate at 450 nm and 630 nm immediately after adding Stop solution. DO NOT exceed 5 minutes. |        |            |             |   |  |  |  |

# 9. Validation Data

# 9.1 Standard curve

These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.



| (pg/mL) | 0.D            | Average | Corrected |
|---------|----------------|---------|-----------|
| 0       | 0.019<br>0.020 | 0.020   | -         |
| 7.8     | 0.172<br>0.173 | 0.173   | 0.153     |
| 15.6    | 0.293<br>0.283 | 0.288   | 0.269     |
| 31.25   | 0.497<br>0.517 | 0.507   | 0.488     |
| 62.5    | 0.800<br>0.849 | 0.825   | 0.805     |
| 125     | 1.203<br>1.212 | 1.208   | 1.188     |
| 250     | 1.644<br>1.659 | 1.652   | 1.632     |
| 500     | 2.054<br>2.143 | 2.099   | 2.079     |

# 9.2 Precision

**Intra-assay Precision** (Precision within an assay) Three samples of known concentration were tested 20 times on one plate to assess intra-assay precision.

**Inter-assay Precision** (Precision between assays) Three samples of known concentration were tested in 24 separate assays to assess inter-assay precision.

| Intra-assay Precision |    |              |     |     | Inter-assay Precision |        |    |              |      |     |
|-----------------------|----|--------------|-----|-----|-----------------------|--------|----|--------------|------|-----|
| Sample                | n  | Mean (pg/mL) | SD  | CV% |                       | Sample | n  | Mean (pg/mL) | SD   | CV% |
| 1                     | 20 | 196.3        | 8.3 | 4.2 |                       | 1      | 24 | 182.2        | 14.5 | 8.0 |
| 2                     | 20 | 46.8         | 2.0 | 4.2 |                       | 2      | 24 | 42.6         | 1.6  | 3.7 |
| 3                     | 20 | 11.3         | 0.6 | 4.9 |                       | 3      | 24 | 9.4          | 0.3  | 3.7 |

## 9.3 Recovery

The recovery of human BAFF spiked to three different levels throughout the range of the assay in various matrices was evaluated.

| Sample Type              |       | Average% of Expected | Range (%) |
|--------------------------|-------|----------------------|-----------|
| Human corum              | 1:30  | 86                   | 72-102    |
| Human serum              | 1:60  | 110                  | 84-125    |
| Coll culture cupernatant | 1:120 | 106                  | 83-128    |
| Cell culture supernatant | 1:240 | 98                   | 75-124    |

#### 9.4 Sample values

Human serum and plasma samples from volunteers were evaluated for human BAFF in this assay. No medical histories were available for the donors used in this study.

| Sample Type        | Mean (pg/mL) | Range (pg/mL) |
|--------------------|--------------|---------------|
| Human serum (n=16) | 564.0        | 202.5-2,595.2 |

U937 human histiocytic lymphoma cells were cultured in RPMI supplemented with 10% fetal bovine serum and 2 mM Lglutamine, and incubated for 7 days at 37 °C. An aliquot of the cell culture supernatant was removed, assayed for human BAFF, and measured 1,603.8 pg/mL.

# 9.5 Sensitivity

The minimum detectable dose of human BAFF is 0.5 pg/mL. This was determined by adding two standard deviations to the concentration corresponding to the mean O.D. of 20 zero standard replicates.



# 9.6 Linearity

To assess the linearity of the assay, samples were diluted with the appropriate **Sample Diluent** to produce samples with values within the dynamic range of the assay.

(The human serum samples were initially diluted 1:4. The cell culture supernatant was initially diluted 1:15. )

|      |                      | Human serum | Cell culture supernatant |
|------|----------------------|-------------|--------------------------|
| 1:2  | Average% of Expected | 100         | 100                      |
| 1:2  | Range (%)            | -           | -                        |
| 1./  | Average% of Expected | 109         | 101                      |
| 1:4  | Range (%)            | 98-116      | 98-104                   |
| 1.0  | Average% of Expected | 119         | 103                      |
| 1:8  | Range (%)            | 111-126     | 96-110                   |
|      | Average% of Expected | 126         | 103                      |
| 1:16 | Range (%)            | 122-129     | 99-107                   |

#### **10. References**

- Le Pottier L, Bendaoud B, Renaudineau Y, Youinou P, Pers JO, Daridon C. New ELISA for B cell-activating factor. Clin Chem. 2009 Oct;55(10):1843-51. doi: 10.1373/clinchem.2009.129940. Epub 2009 Aug 20. PMID: 19696115.
- Krumbholz M, Theil D, Derfuss T, Rosenwald A, Schrader F, Monoranu CM, Kalled SL, Hess DM, Serafini B, Aloisi F, Wekerle H, Hohlfeld R, Meinl E. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med. 2005 Jan 17;201(2):195-200. doi: 10.1084/jem.20041674. Epub 2005 Jan 10. PMID: 15642740; PMCID: PMC2212784.
- Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum. 2006 Jan;54(1):192-201. doi: 10.1002/art.21526. PMID: 16385515.
- Zhu XJ, Shi Y, Peng J, Guo CS, Shan NN, Qin P, Ji XB, Hou M. The effects of BAFF and BAFF-R-Fc fusion protein in immune thrombocytopenia. Blood. 2009 Dec 17;114(26):5362-7. doi: 10.1182/blood-2009-05-217513. Epub 2009 Sep 30. PMID: 19794139.

